콘텐츠로 건너뛰기
Merck
모든 사진(3)

주요 문서

699800P

Avanti

MPLA (PHAD)

Avanti Research - A Croda Brand

동의어(들):

PHAD phosphorylated hexaacyl disaccharide; Glycopyranoside Lipid A; GLA

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C96H184N3O22P
CAS Number:
Molecular Weight:
1763.47
MDL number:
UNSPSC 코드:
12352211
NACRES:
NA.25

설명

Monophosphoryl Lipid A (Synthetic) (PHAD)

분석

>99% (HPLC)

양식

powder

포장

pkg of 1 × 1 mg (699800P-1mg)
pkg of 1 × 5 mg (699800P-5mg)

제조업체/상표

Avanti Research - A Croda Brand

응용 분야

vaccine development

배송 상태

dry ice

저장 온도

−20°C

일반 설명

Monophosphoryl lipid A (MPLA) is either extracted from bacterial lipid A or by chemical synthesis.
Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

애플리케이션

MPLA PHAD has been used:
  • as a component of cobalt porphyrin-phospholipid (Co-PoP) liposomes for the immunization of mice with membrane proximal external region (MPER) of the gp41 envelope protein
  • as an adjuvant along with dimethyldioctadecylammonium bromide(DDA) for C. muridarum recombinant membrane protein based multi-subunit vaccine
  • as toll-like receptor-4 (TLR4) agonist adjuvant for respiratory syncytial virus (RSV) fusion (F) protein FI-RSV vaccine

생화학적/생리학적 작용

Monophosphoryl lipid A (MPLA) is a natural agonist for the toll-like receptor-4 (TLR4). It is useful as an adjuvant in immunization. MPLA is a safe prophylactic agent and has immunotherapeutic applications. MPLA used in vaccination improves B cell and T cell-mediated immunity.

포장

2 mL Amber Glass Crimp Cap Vial (699800P-1mg)
2 mL Amber Glass Crimp Cap Vial (699800P-5mg)

기타 정보

For R&D use only. Not for drug, household, or other uses.

법적 정보

Avanti Research is a trademark of Avanti Polar Lipids, LLC
PHAD is a trademark of Avanti Polar Lipids, LLC

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

죄송합니다. 지금은 이 제품에 대한 COA이(가) 온라인에서 제공되지 않습니다.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

이미 열람한 고객

Susana Lousada-Dietrich et al.
Vaccine, 29(17), 3284-3292 (2011-02-26)
GMZ2 adjuvanted by aluminum hydroxide is a candidate malaria vaccine that has successfully passed phase 1 clinical testing in adult German and Gabonese volunteers and Gabonese children under five. Here we report a preclinical study screening a series of adjuvant
Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens
Shao S, et al.
Nature Chemistry, 7(5), 438-438 (2015)
Rhea N Coler et al.
PloS one, 6(1), e16333-e16333 (2011-02-08)
Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I
Katharina Richard et al.
Vaccine, 38(27), 4298-4308 (2020-05-12)
Toll-like receptors (TLRs), a family of "pattern recognition receptors," bind microbial and host-derived molecules, leading to intracellular signaling and proinflammatory gene expression. TLR4 is unique in that ligand-mediated activation requires the co-receptor myeloid differentiation 2 (MD2) to initiate two signaling
Caroline Boudousquié et al.
Vaccines, 8(1) (2020-01-18)
With the emergence of immune checkpoint inhibitors and adoptive T-cell therapies, there is a considerable interest in using personalized autologous dendritic cell (DC) vaccines in combination with T cell-targeting immunotherapies to potentially maximize the therapeutic impact of DC vaccines. Here

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.